Goldman Sachs
FLNA

Goldman Sachs’s Filana Therapeutics FLNA Stock Holding History

Goldman Sachs’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-17,800
Closed -$220K – 6036
2024
Q2 		$220K Buy
+17,800
New +$375K ﹤0.01% 5222
2016
Q4 		– Sell
-357
Closed -$2K – 7064
2016
Q3 		$2K Buy
+357
New +$5.92K ﹤0.01% 6969
2013
Q3 		– Sell
-4,643
Closed -$72K – 6673
2013
Q2 		$72K Buy
+4,643
New +$98.1K ﹤0.01% 5963

Other funds holding FLNA

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Goldman Sachs's FLNA Position: Q1 2026 in Review

Goldman Sachs increased its Filana Therapeutics (FLNA) stake by 25% in Q1 2026, buying an estimated $17.2K and bringing the position to 41,324 shares worth $69.8K. The position accounts for ﹤0.01% of the portfolio, ranked #6258.

Goldman Sachs first reported a position in FLNA in Q2 2013 and has held it in 34 quarters since. The position peaked at $5.57M in Q2 2021. 101 funds tracked by Wall St. Rank hold FLNA as of Q1 2026.

  • Goldman Sachs held 41,324 shares of Filana Therapeutics worth $69.8K as of Q1 2026.
  • Goldman Sachs bought 8,335 Filana Therapeutics shares in Q1 2026, an estimated $17.2K.
  • Filana Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #6258 holding.
  • Goldman Sachs first reported a position in Filana Therapeutics in Q2 2013 and has held it in 34 quarters since.
  • Goldman Sachs's Filana Therapeutics position peaked at $5.57M in Q2 2021.
  • 101 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.